stethoscope

Join our network and find credentialing information.

Log in to Availity Essentials™ to access patient benefits, claims information and more.

Find tools and materials to support doing business with us.

Learn more about research and trends that impact your practice.

Find self-service info and phone numbers and update your provider data.

Review prior authorization lists for services, medications and submission guidance.

Prior authorization submission information

Professionally administered drugs prior authorization

Find appeals guidelines and payment policy information.

Learn how to submit claims and find coding guidance.

Find policies for procedures, devices and medications.

Review guidelines and health programs to support your patients and practice.

Find dental benefits, tools and resources.

Prior authorization for professionally administered drugs 

Locate state-specific resources for Humana Healthy Horizons® (Medicaid).

compass

Shop plans, learn about Medicare and explore member resources.

Search for in-network medical, vision, dental and pharmacy providers.

Drug recall notice for Taro Pharmaceuticals phenytoin oral suspension

A couple researching a prescription online

To assist you in the care of your patients, we would like to alert you to the recall of two lots of Taro Pharmaceuticals phenytoin oral suspension USP, 125 mg/5 mL, both in 237 mL bottles, on Feb. 20, 2020.1,2 We recommend you review your medical records and contact all patients for whom you have prescribed this medication to warn them of the recall. We have listed alternative options below.

Taro voluntarily recalled these lots of phenytoin oral suspension because the product may not re-suspend when shaken, as instructed for administration, which could result in under- or overdosing. This recall is being conducted with the knowledge of the U.S. Food and Drug Administration (FDA).

The population at risk of adverse effects is primarily infants and young children. In those patients, inaccurate dosing might result in serious adverse effects, such as intoxication or breakthrough seizures requiring medical intervention. For a small minority of patients who might have severe or repeated breakthrough seizures, a drop in their phenytoin blood levels could result in life-threatening status epilepticus requiring immediate emergency room treatment. To date, Taro has not received any reports of adverse events related to use of the product as part of this recall.

Information for providers:1,2

    We have sent a letter to your patients who have had a claim for Taro phenytoin oral suspension and asked them to contact their physicians or healthcare providers if their medication is included in the recall and if they have experienced problems that may be related to using these drug products.

    Healthcare providers with questions can contact Taro by calling 1-866-705-1553 or by email at TaroPVUS@taro.com, Monday through Friday, from 7 a.m. to 7 p.m., Central time.

    Patients may report adverse reactions or quality problems experienced with the use of this product to the FDA’s MedWatch Adverse Event Reporting program either online, by regular mail or by fax.            Online: Complete and submit the        report.                    Select “Consumer/Patient (FDA Form 3500B).”



        Regular mail or fax: Download the        form.                    Select “Form FDA 3500B – Voluntary Reporting for Consumers” and submit by mail to the address on the form or by fax to 1-800-FDA-0178.







    “Taro Pharmaceuticals U.S.A. Issues Voluntary Nationwide Recall of Phenytoin Oral Suspension USP, 125 mg/5ml Due to Possible Underdosing or Overdosing.” U.S. Food and Drug Administration. Feb. 21, 2020.    www.fda.gov/safety/recalls-market-withdrawals-safety-alerts/taro-pharmaceuticals-usa-issues-voluntary-nationwide-recall-phenytoin-oral-suspension-usp-125-mg5ml

    “Taro Pharmaceuticals U.S.A. Issues Voluntary Nationwide Recall of Phenytoin Oral Suspension USP, 125 mg/5 mL Due to Possible Underdosing or Overdosing.” Taro Pharmaceutical Industries Ltd. Feb. 20, 2020.    https://taro.gcs-web.com/news-releases/news-release-details/taro-pharmaceuticals-usa-issues-voluntary-nationwide-recall



Drug recall notice for quinapril products

Drug recall notice for Nature-Throid and WP Thyroid tablets

Drug recall notice for Belviq, Belviq XR (lorcaserin)

Drug recall notice for NP Thyroid tablets

Formulary changes for generic Ventolin HFA

Impact of ongoing angiotensin II receptor blocker drug recalls

Product name	NDC number	Lot number	Expiration date
phenytoin oral suspension 125 mg/5 mL	51672-4069-1	327874	December 2020
phenytoin oral suspension 125 mg/5 mL	51672-4069-1	327876	December 2020

Medication	Manufacturer	NDC number
phenytoin 125 mg/5 mL suspension	Greenstone LLC	59762-0531
phenytoin 125 mg/5 mL suspension	Morton Grove Pharmaceuticals Inc.	60432-0131
phenytoin 125 mg/5 mL suspension	VistaPharm Inc.	66689-0036
phenytoin 125 mg/5 mL suspension	VistaPharm Inc.	66689-0775

References:

Pharmacy news